First Light Asset Management’s Agile Therapeutics AGRX Stock Holding History

First Light Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-23	Closed	-$264K	–	55
2016 Q4	$264K	Buy	23 +4	+21%	+$56K	0.12%	49
2016 Q3	$261K	Sell	19 -11	-37%	-$157K	0.11%	64
2016 Q2	$454K	Sell	30 -1	-3%	-$13.7K	0.21%	50
2016 Q1	$382K	Buy	+31	New	+$400K	0.19%	56

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

First Light Asset Management's AGRX Position: Q1 2017 in Review

First Light Asset Management sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 23 shares — an estimated $264K sold.

First Light Asset Management first reported a position in AGRX in Q1 2016 and held it in 4 quarters. The position peaked at $454K in Q2 2016. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

First Light Asset Management reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
First Light Asset Management sold 23 Agile Therapeutics shares in Q1 2017, an estimated $264K.
First Light Asset Management first reported a position in Agile Therapeutics in Q1 2016 and held it in 4 quarters.
First Light Asset Management's Agile Therapeutics position peaked at $454K in Q2 2016.
48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on First Light Asset Management's 13F filing for Q1 2017, filed 15 May 2017.